ArticleDiabetology & metabolic syndrome2025
Determinants of time to severe in-stent restenosis in patients with diabetes mellitus after drug-eluting coronary stenting.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite advances in drug-eluting stents (DES), patients with diabetes mellitus (DM) remain at 1.5-2 times higher risk of in-stent restenosis (ISR) than non-diabetics. However, the temporal progression and predictors of severe ISR in this population are not well defined.
methodsA retrospective cohort analysis was conducted on 323 diabetic patients who underwent follow-up angiography after everolimus-eluting coronary stenting at a single center between May 2017 to December 2024. The primary outcome was the time to severe ISR (defined as ≥ 70% luminal narrowing). Demographic, clinical, metabolic (including METS-IR), and procedural (Gensini score, lesion characteristics) variables were analyzed. Cox regression identified predictors of accelerated restenosis, and a risk-stratification model was developed and validated internally.
resultsThe median time to severe ISR was 7 months. Independent predictors included elevated D-dimer (HR = 1.001, p = 0.0004), BNP (HR = 1.001, p = 0.0001), METS-IR (HR = 1.378, p = 0.012), Gensini score (HR = 1.004, p = 0.032), and bilateral lesions (HR = 1.242, p = 0.03). Older age was identified as a protective factor, as was higher hemoglobin too. The risk model showed moderate discrimination (AUC = 0.702; sensitivity 68%; specificity 67%) and clinical utility on decision-curve analysis.
conclusionSevere ISR manifests early in diabetics, driven by metabolic dysregulation, thrombotic activity, and procedural complexity. The validated risk-stratification model facilitates personalized surveillance and targeted interventions to mitigate the ISR burden on this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.